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In the UK, 10% of patients diagnosed with rectal cancer have inoperable disease at presentation. This study ascertained whether the
resectability rate of inoperable locally advanced rectal cancer was improved by administration of intravenous irinotecan, 5-fluorouracil
(5-FU) and pelvic radiotherapy. During phase I of the trial (n¼12), the dose of irinotecan was escalated in three-patient cohorts from
50mgm
 2 to 60mgm
 2 to 70mgm
 2 to identify the maximum tolerated dose (60mgm
 2). In phase II, 31 patients with non-
resectable disease received 45Gy radiotherapy and 5-FU infusions (200mgm
 2 per day) for 5 weeks. Irinotecan (60mgm
 2) was
given on days 1, 8, 15 and 22. After treatment, patients were operated on if possible. Thirty patients completed the protocol, 28
underwent surgery. Before surgery, MRI restaging of 24 patients showed that 19 (79%) had a reduction in tumour stage after
treatment (seven complete clinical response and 12 partial). Of 27 patients followed up after surgery, 22 (81%) had clear
circumferential resection margins. Disease-free and overall survival estimates at 3 years were 65 and 90%, respectively. The regimen
was well tolerated. Irinotecan, 5-FU and radiotherapy results in tumour downgrading, allowing resection of previously inoperable
tumour with acceptable toxicity.
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More than 13000 new cases of rectal cancer are diagnosed every
year in the UK (Office for National Statistics, 2003; Northern
Ireland Cancer Registry, 2007; Welsh Cancer Intelligence and
Surveillance Unit, 2007). At least 10% of these cancers are
inoperable because of involvement of, or penetration through,
the mesorectal fascia and implication of other organs (Devita et al,
2001). For patients with inoperable disease, prognosis is poor.
Radiotherapy and, more recently, combined chemo-radiotherapy
(CRT) regimens have been shown to be able to reduce the stage
and size of advanced tumours, making them amenable to
resection. The ideal combined-modality pre-operative regimen is,
however, yet to be determined.
To date, phase I/II trials have assessed the effect of radiation in
combination with 5-fluorouracil (5-FU) or another fluoropyrimi-
dine with or without leucovorin (to enhance the actions of 5-FU)
(Videtic et al, 1998; Rodel et al, 2000). Post-operative chemother-
apy is also sometimes included in the CRT regimen (Minsky et al,
1993). Overall, results from these studies have been favourable,
resulting in the widespread adoption of CRT regimens, mostly
based on 5-FU, in the neoadjuvant treatment of inoperable rectal
cancer.
Recently, several novel therapies have emerged with activity in
rectal cancer. These include raltitrexed, irinotecan, oxaliplatin and
oral fluoropyrimidines, including uracil-tegafur and capecitabine
(de la Torre et al, 1999; Kalofonos et al, 2003; Fernandez-Martos
et al, 2004; Gambacorta et al, 2004a,b; Hofheinz et al, 2005;
Klautke et al, 2005, 2006). Despite the advent of oral fluoro-
pyrimidines, intravenous infusion remains popular in Europe and
the United States, because nausea, vomiting and diarrhoea can
affect compliance and absorption of oral drugs (Minsky et al, 1993;
Rodel et al, 2000; Mohiuddin et al, 2006). For metastatic colorectal
cancer, the addition of irinotecan to treatment with 5-FU and
leucovorin significantly improves progression-free and overall
survival (Douillard et al, 2000; Saltz et al, 2000). This finding has
resulted in an interest in developing its use as part of a combined
protocol for the treatment of locally advanced disease.
Several phase I and phase II trials have investigated the use of
irinotecan as a radiation sensitizer in CRT regimens for locally
advanced rectal cancer; however, results are mostly published as
meeting abstracts, with short-term follow up only. Irinotecan has
been administered as monotherapy combined with radiation, but
most of the studies have assessed the CRT regimen of irinotecan
plus 5-FU and radiotherapy (Minsky et al, 1999; Klautke et al,
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s2001, 2005, 2006; Kalofonos et al, 2003; Mehta et al, 2003;
Navarro et al, 2003, 2007; Mitchell et al, 2004; Sebag-Montefiore
et al, 2005).
Overall, the results of these preliminary studies suggest
promising activity of irinotecan-containing regimens. Six small
studies are published as full papers (Kalofonos et al, 2003; Mehta
et al, 2003; Klautke et al, 2005; Mohiuddin et al, 2006; Glynne-
Jones et al, 2007; Willeke et al, 2007). To conclude, the combined
RCT regimen irinotecan plus 5-FU with radiation therapy appears
to be a tolerable adjuvant therapy (Kalofonos et al, 2003) that
results in a good tumour response when given pre-operatively to
patients with rectal cancer in whom resection is either possible or
uncertain (Mehta et al, 2003; Klautke et al, 2005).
This current study was undertaken to rigorously assess and
provide long-term follow-up data for the use of irinotecan in
combination with 5-FU and radiotherapy for inoperable, locally
advanced (T3/T4) rectal tumours. The aims of this study are two
fold: (a) to establish a safe dose of intravenous (iv) irinotecan for
administration in combination with a standard course of 5-FU and
concomitant pelvic radiotherapy to patients with locally advanced
non-resectable rectal cancer and (b) to assess the effectiveness of
the regimen, in terms of post-treatment resectability of tumours,
and disease-free and overall survival.
MATERIALS AND METHODS
Participants
Patients with unresectable rectal cancer were recruited between
September 2001 and December 2003 from four centres in the UK:
the Christie Hospital NHS Trust, Manchester; Clatterbridge
Hospital, Liverpool; North Wales Cancer Treatment Centre, Rhyl;
and the Royal Preston Hospital, Preston.
The tumour stage of all patients was determined clinically after
examination under general anaesthetic and following computed
tomography (CT) of the chest, abdomen and pelvis, or magnetic
resonance imaging (MRI) of the abdomen or pelvis. In cases of
discrepancy, the highest tumour stage was used. All recruited
patients were diagnosed as having non-resectable disease, defined
as involving the edge of the mesorectal fascia or adherence of the
tumour to an adjacent structure or organ, preventing an attempt at
resection with a negative circumferential resection margin (CRM).
The patients had a WHO performance score of less than two
and adequate hepatic and renal function (bilirubin, creatinine,
aspartate aminotransferase or alanine aminotransferase o2.5 
upper limit of normal) and bone marrow reserve (absolute
neutrophil count 42.0 10
9; platelets 4100 10
9; haemoglobin
410.0gl
 1).
Patients were excluded if they had received previous radio-
therapy or chemotherapy, had been diagnosed with metastatic
disease or had a past or current malignancy at other sites (with the
exception of adequately treated in-situ carcinoma of the cervix
uteri and non-melanoma carcinoma of the skin).
All patients provided written informed consent and the study
was performed in accordance with the ethical principles outlined
in the declaration of Helsinki. Ethical approval for this study was
obtained from the ethics committees of all participating centres.
Procedure
Radiotherapy was given by planned target volume to the pelvic
area, treating with 25 fractions at 1.8Gy/fraction via four fields,
with all fields treated daily (45Gy total dose). The planned target
volume was defined using simulator or CT planning. The planned
target volume was to include: 3cm superior, inferior and lateral of
the extent of the gross tumour volume, but no higher than the
sacral promontory; the posterior border of the most posterior
aspect of the sacrum; and 2cm anterior to the tumour or the
anterior rectal wall, whichever was the most anterior. Treatment
was given from Monday to Friday for 5 weeks.
5-FU 200mgm
 2 per day was administered by continuous iv
infusion 7 days/week throughout radiotherapy. Irinotecan
(50–70mgm
 2) was administered on days 1, 8, 15 and 22 via a
30-min iv infusion (day 1 being the first day of radiotherapy;
Figure 1).
During phase I of the study, cohorts of three patients received
irinotecan in a dose escalating between 50 and 70mgm
 2.
Development of grade III and IV toxicity guided the calculation
of the maximum-tolerated dose. Toxicity assessments were made
according to the National Cancer Institute Common Toxicity
Criteria version 3.0. In the event of non-haematological toxicity,
the dose was modified as follows: for grade I toxicity, no treatment
modification was made; for grade II toxicity, 5-FU and irinotecan
were interrupted until resolution to grade 0, then resumed at full
dose; for grade III toxicity, 5-FU and irinotecan were interrupted
until resolution to grade 0, then resumed at 75% of the initial dose.
For patients with grade II or grade III toxicity, radiotherapy was
continued, but reviewed daily. For those with grade IV toxicity,
5-FU and irinotecan were discontinued and radiotherapy was
interrupted; if symptoms did not resolve to grades 0–I within 2
weeks, radiotherapy was permanently discontinued.
Total mesorectal excisional (TME) surgery was planned 6–8
weeks after the completion of CRT in all patients. Note that only 28
of 31 had surgery, however, since two developed metastatic disease
and one had a myocardial infarction prior to surgery.
Tumour response
Every patient’s treatment response was measured clinically and
pathologically. Tumours were staged clinically, according to the
TNM (tumour, node, metastasis) system from both pre-surgical
and post-surgical CT/MRI scans. Tumour downstaging was
considered complete when all lesions disappeared, and partial
when tumour size decreased by more than 30%. Disease was
considered to be progressive if tumour size increased by more than
20% (maximum transaxial or craniocaudal dimension). Stable
Day 1 8 15 22 29
Radiotherapy (45 Gy in 
25 daily fractions)
Irinotecan (60 mg m
–2 per week)
5-FU (200 mg m–2 day–1
continuous)
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Figure 1 Patient treatment. 5-FU¼5-fluorouracil.
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sdisease was defined as tumours that decreased by less than 30% or
increased by less than 20%, using the RECIST criteria (response
evaluation criteria in solid tumours) (Therasse et al, 2000).
Patients were seen at least once a week during CRT, then weekly
for 6 weeks after the end of radiotherapy.
Tumours that were resected after CRT were also classified by
histopathology. The presence of residual disease macroscopically
at surgery and microscopically in terms of tumour involvement
(or clearance) at the CRM was used to classify the surgical
resection as R2 (macroscopic residual disease), R1 (microscopic
residual disease—CRM involved or disease within 1mm of the
CRM) or R0 (confirmed clear margins—CRM negative). A
pathological complete response was recorded when no tumour
was seen. Tumours in which only a few abnormal cells were seen
without a residual tumour mass were considered indicative of
microfocal residual disease. Pathological Dukes’ staging was also
recorded.
After surgery, patients were followed up by the treating surgeon,
according to the local protocol, at a maximum interval of every
6 months; serial carcinoembryonic antigen estimation was
performed for up to 5 years. CT scanning of the abdomen and
pelvis was also carried out at 6, 12 and 24 months following
surgery.
Statistical analysis
The probabilities of disease-free and overall survival were
calculated using the Kaplan Meier method. Disease-free and
overall survival rates were calculated from the date of registration
to the time of death or relapse. Disease-free survival was defined as
the absence of relapse or recurrence of the primary cancer or death
from any cause.
RESULTS
Dose escalation and patient characteristics
Twelve patients were recruited for phase I of the study. In the first
cohort of three patients, who received irinotecan 50mgm
 2, there
was one episode of grade III diarrhoea. Three more patients were
enrolled for treatment with this dose, and none experienced a
grade III or grade IV dose-limiting toxicity (DLT). There was also
no DLT in the cohort of three patients who received irinotecan
60mgm
 2. However, two of the three patients in the cohort
receiving irinotecan 70mgm
 2 experienced a DLT.
For phase II of the study, data were collected for 31 patients
(23 (74%) men, eight (26%) women) aged 37–76 years (mean 61.8
years), with inoperable rectal cancer. All had threatened CRM and
clinically fixed tumour as judged by examination under anaes-
thetic and CT and/or MR imaging. In all 20 patients had tumours
0–5cm from the anal verge, six 5–10cm and five 10–15cm. They
were treated with the maximum tolerated dose of irinotecan, which
was judged to be 60mgm
 2 on the basis of results from the phase I
trial.
CRT administration and tolerability
One patient requested discontinuation of chemotherapy after 4
weeks of treatment, having previously required reductions in the
irinotecan dose, but completed radiotherapy and subsequently
underwent surgery. The other thirty (97%) patients received the
prescribed four doses of irinotecan. Patients who completed the
treatment protocol received a mean of 34.3 days (range, 28–35
days) of continuous iv 5-FU infusion. The 5-FU dose was reduced
in three (10%) patients; in two of these patients, the dose was
reduced because of adverse events (pyrexia and diarrhoea) and in
one the dose reduction was the result of an administration error.
A mean radiation dose of 44.7Gy (range, 37.8–45.0Gy) was
administered to patients who completed treatment. Only two
patients had their total radiotherapy dose reduced. The toxicity
observed was generally mild. The most frequent grade III toxicities
experienced by the cohort were diarrhoea (n¼4 (13%)) and
constipation (n¼2 (6%)). Only one (3%) patient experienced
grade IV toxicity, which was fever without infection. The incidence
of grade III and grade IV toxicities experienced by patients during
treatment is given in Table 1. One patient died from an unrelated
myocardial infarction approximately 4 weeks post-treatment and
two patients were diagnosed with metastatic disease shortly after
completing the full treatment protocol.
Twenty-eight patients underwent surgery. One patient died in
the immediate post-operative period from an anastomotic leak; 27
patients were evaluable for follow-up after resection.
CRT efficacy
All of the patients recruited underwent staging before treatment
(n¼31). In 21 (68%) patients the tumour was classified as T3,
and in 10 (32%) as T4. Eleven (35%) patients had no nodal
metastases (N0), 15 (48%) were staged as N1 and five (16%) were
staged as N2.
Before surgery, 24 of 28 (86%) patients underwent repeat staging
with pelvic MRI. Of these, seven (29%) were judged to have a
complete clinical response, 12 (50%) a partial clinical response and
four (17%) stable disease. One (4%) patient showed progressive
disease on this MRI scan. Therefore, 19 of 24 (79%) patients
assessed by MRI before surgery had downsized tumours on clinical
staging.
In total, 28 of 31 (90%) patients underwent surgical resection
and 27 of 31 (87%) had complete macroscopic resections. Surgery
was performed 6–8 weeks after the end of radiotherapy. From the
macroscopic and microscopic histopathology reports, patients’
residual disease was summarised as R0 in 22 of 27 (81%) patients,
R1 in four (15%) patients and as R2 in one (4%) patient.
Histological staging of the evaluable patients after surgery
revealed five of 27 (19%) patients in whom there was a pathological
complete response. Four of the 27 (15%) patients had minimal
residual (microfocal) disease. Eight of the 27 (30%) patients had
Dukes’ stage B disease and 10 (37%) patients had Dukes’ stage C
disease.
After a median follow-up of 24 months (range, 8–43 months),
11 of 31 (35%) patients who were enrolled had experienced disease
progression (two of these occurred pre-operatively) and three
(10%) patients had died of their disease. There were five local
recurrences in the pelvis—two with distant spread beyond the
pelvis and three with local recurrence. Six (19%) patients relapsed
with metastatic disease only. Of the patients who died, one death
was the result of local progression of rectal cancer without distant
spread, and two deaths were due to metastatic disease without
Table 1 Grade III and Grade IV toxicities experienced by patients during
treatment
Toxicity Grade III, n (%) Grade IV, n (%)
Diarrhoea 4 (13) 0 (0)
Constipation 2 (6) 0 (0)
Skin sores 1 (3) 0 (0)
Lethargy 1 (3) 0 (0)
Infection 1 (3) 0 (0)
Abdominal cramping 1 (3) 0 (0)
Chest pain 1 (3) 0 (0)
Fever (without infection) 0 (0) 1 (3)
Grade III/IV neutropenia 0 (0) 0 (0)
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slocal relapse. The estimate for 3-year relapse-free survival was 65%
(Figure 2), and the estimate for 3-year overall survival was 90%
(Figure 3).
DISCUSSION
The results of this study suggest that even the most locally
advanced rectal cancer can be downstaged and rendered operable,
or even cured, by use of an appropriate CRT regimen.
Furthermore, the short-term and long-term morbidity of irinote-
can in combination with 5-FU and radiotherapy is acceptable, and
follow-up has revealed excellent local and distant disease control.
Other studies have not produced such good results with such low
toxicity; however, this is a phase I/II study with carefully selected
patients, and further work is needed to confirm these preliminary
findings.
Of 31 patients with non-resectable stage T3/T4 rectal cancer, 28
(90%) underwent TME surgical resection of their tumour following
treatment with irinotecan, 5-FU and radiotherapy. Complete
surgical resection (R0 or R1) was achieved in 26 patients (84% of
the initial 31, or 96% of all those who were assessable post-
surgery). The R0 rate for all patients was 22/31 (71%), or 22/27
(81%) of those assessable post-surgery.
Phase II trials rarely include a comparator group, making the
results from a single study difficult to assess in isolation. While
comparisons between studies are limited because of inherent
variability in patients, disease severity and treatments, an
assessment of the relative efficacy and tolerability of a treatment
is nevertheless helpful for determining whether a regimen offers
potential benefits, justifying further study.
Prior to this study, it was thought that the problematic side
effect of diarrhoea associated with each of irinotecan, 5-FU and
radiation would cause severe toxicity should the agents be
combined, rendering the regimen too toxic for routine use.
However, the rate of grade III/IV toxicity (10%) noted in this study
is comparable with that reported for oxaliplatin regimes (18–30%)
(Alonso et al, 2004, 2007; Casado et al, 2004; Tucci et al, 2004;
Fakih et al, 2005; Machiels et al, 2005; Avallone et al, 2006;
Rutten et al, 2006; Ro ¨del et al, 2007). Indeed, the findings of this
study suggest a safety profile for irinotecan, 5-FU and radiotherapy
that is comparable with previously reported findings with
capecitabine and radiotherapy (rate of grade III/IV diarrhoea
12–28%) (Mehta et al, 2003; Navarro et al, 2003; Mitchell et al,
2004; Mohiuddin et al, 2006; Willeke et al, 2007), but using a
lower radiation dose (45Gy as opposed to 50.4Gy in the
capecitabine regimen).
Furthermore, the resection rate achieved in this study is higher
than that observed in studies using radiotherapy alone (range,
64–75%) (Emami et al, 1982; Frykholm et al, 2001) or in some
studies of CRT regimens (62–95%) (de la Torre et al, 1999;
Frykholm et al, 2001; Klautke et al, 2006; Glynne-Jones et al, 2007),
and it is comparable to that cited in other reports of research with
irinotecan (90–100%) (Minsky et al, 1999; Mitchell et al, 2004;
Klautke et al, 2005; Sebag-Montefiore et al, 2005). It is worth
noting, that this current trial included only patients with T3/T4
cancers—that is patients with more advanced disease than those
included in previously published studies.
Clinical staging in this study was performed by CT/MRI in a
subset of patients after CRT treatment. At the time that the study
was conducted, CT/MRI was used for investigational purposes only
and was, therefore, not undertaken in all of the patients. Clinical
staging revealed a complete clinical response rate of 29, and 79% of
patients were judged to have downstaged tumours on MRI after
treatment. Few studies have reported MR downstaging following
CRT, although in a previous study of 31 patients treated with 5-FU
and radiotherapy the tumour volume was decreased by at least half
in 77% of patients (Glynne-Jones et al, 2007).
The proportion of patients obtaining a pathological complete
response (19%) was similar to that reported for some other
irinotecan-based protocols (11–25%) (Mitchell et al, 2004; Klautke
et al, 2005; Sebag-Montefiore et al, 2005). Considering all
irinotecan-based protocols together, the pathological complete
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Figure 3 Overall survival in patients who underwent surgical resection.
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Figure 2 Relapse-free survival in patients who underwent surgical
resection. The curve begins below 100% survival at time 0 because one
patient died in the immediate post-operative period and was considered to
have died without ever being disease-free.
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sresponse seems to be greater than that observed with radiotherapy
alone (4%) (Frykholm et al, 2001) and comparable with most other
fluoropyrimidine CRT regimens (12–28%) (de la Torre et al, 1999;
Freyer et al, 2001; Frykholm et al, 2001; Carraro et al, 2002; Ge ´rard
et al, 2003; Aschele et al, 2005; Loi et al, 2005; Avallone et al, 2006;
Klautke et al, 2006; Pucciarelli et al, 2006; Ryan et al, 2006). Four
(15%) patients in the current study had microfocal residual
disease, meaning overall that nine (29% of the phase II patient
population) patients had a complete, or almost complete, response
to treatment.
Considering CRM involvement, 81% of patients in this study
who underwent TME surgery were classed as R0 after surgery
(CRM-negative). In studies that report data on the number of
CRM-negative cases, results range from 61–74% with radiotherapy
(Emami et al, 1982; Frykholm et al, 2001) to 72–89% with 5-FU-
based protocols (de la Torre et al, 1999; Frykholm et al, 2001;
Avallone et al, 2006; Klautke et al, 2006; Glynne-Jones et al, 2007)
or 88–89% when irinotecan is given as part of the CRT regimen
(Klautke et al, 2005; Sebag-Montefiore et al, 2005). The addition of
irinotecan to CRT regimens does not, therefore, seem to increase
the high rate of CRM-negative surgery reported previously,
but CRT certainly seems to be more successful than radio-
therapy alone.
It should be noted that many of the studies mentioned above did
not use CT/MRI to assess CRM involvement pre-treatment, but
relied on clinical examination alone. Patients with early-stage
tumours may, therefore, have been classified as CRM-negative,
resulting in overestimation of this parameter.
A negative CRM may provide an early surrogate test of efficacy
and a predictor of local recurrence, enabling the rapid evaluation
of the many new treatment regimens currently being investigated
(Cunningham et al, 2002). Patients who respond to pre-operative
chemo-radiation have improved disease-free and overall survival
compared with non-responders (Janjan et al, 2001). Therefore, the
histological complete response rate and the impact of neoadjuvant
therapy on clinical staging are other potential short-term end
points that may be early indicators of disease-free and overall
survival.
Comparison of the disease-free and overall survival results
observed here with those of previous studies is complicated by the
disease severity at recruitment, the duration of follow-up and
whether second colorectal cancers or deaths due to causes other
than rectal cancer are included. The only previous study of
patients with rectal cancer receiving CRT with irinotecan and 5-FU
reporting survival results was in patients with locally advanced
rectal cancer who received neoadjuvant therapy. The 4-year
disease-free and overall survival rates were 73 and 66%,
respectively (Klautke et al, 2005). CRT in patients with non-
resectable rectal cancer has been shown to significantly improve
disease-free survival compared with radiotherapy alone, and may
increase overall survival (Frykholm et al, 2001). Overall survival
rates following CRT treatment with 5-FU have been reported to
range from 26 to 73% (de la Torre et al, 1999; Frykholm et al, 2001;
Avallone et al, 2006; Klautke et al, 2006; Glynne-Jones et al, 2007).
Reported rates of disease-free or relapse-free survival range from
54 to 74% (de la Torre et al, 1999; Frykholm et al, 2001; Avallone
et al, 2006; Klautke et al, 2006; Glynne-Jones et al, 2007), but again
the studies vary in duration of follow-up. The overall and disease-
free survival rates observed in the current study are, on the whole,
greater than those seen previously. A prospective, randomised trial
is now needed to confirm in larger numbers the impact on survival
of adding irinotecan to CRT with 5-FU in patients with
non-resectable rectal cancer.
Further work also continues to investigate whether using oral
fluoropyrimidine capecitabine in place of 5-FU in the regimen can
produce acceptable toxicity rates, especially with respect to
diarrhoea (Gollins et al, 2006). Once complete, a prospective,
randomised phase III study is proposed, comparing irinotecan
5-FU and radiotherapy with (i) irinotecan, capecitabine and
radiotherapy and (ii) oxaliplatin, 5-FU and radiotherapy. This
randomised trial will identify the most effective regimen and
provide important information on whether R0 resection rates
and pathological complete remission rates predict long-term
survival.
When combined with 5-FU and radiotherapy, irinotecan
appears to be both effective and safe for the neoadjuvant treatment
of rectal cancer. The findings published here suggest that
irinotecan has a place in CRT regimens for locally advanced rectal
cancer. The regimen should now be compared with other non-
irinotecan-based CRT regimens in a randomised phase III trial.
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